Literature DB >> 24361861

Altered cortical expression of GABA-related genes in schizophrenia: illness progression vs developmental disturbance.

Gil D Hoftman1, David W Volk2, H Holly Bazmi2, Siyu Li3, Allan R Sampson3, David A Lewis4.   

Abstract

BACKGROUND: Schizophrenia is a neurodevelopmental disorder with altered expression of GABA-related genes in the prefrontal cortex (PFC). However, whether these gene expression abnormalities reflect disturbances in postnatal developmental processes before clinical onset or arise as a consequence of clinical illness remains unclear.
METHODS: Expression levels for 7 GABA-related transcripts (vesicular GABA transporter [vGAT], GABA membrane transporter [GAT1], GABAA receptor subunit α1 [GABRA1] [novel in human and monkey cohorts], glutamic acid decarboxylase 67 [GAD67], parvalbumin, calretinin, and somatostatin [previously reported in human cohort, but not in monkey cohort]) were quantified in the PFC from 42 matched pairs of schizophrenia and comparison subjects and from 49 rhesus monkeys ranging in age from 1 week postnatal to adulthood.
RESULTS: Levels of vGAT and GABRA1, but not of GAT1, messenger RNAs (mRNAs) were lower in the PFC of the schizophrenia subjects. As previously reported, levels of GAD67, parvalbumin, and somatostatin, but not of calretinin, mRNAs were also lower in these subjects. Neither illness duration nor age accounted for the levels of the transcripts with altered expression in schizophrenia. In monkey PFC, developmental changes in expression levels of many of these transcripts were in the opposite direction of the changes observed in schizophrenia. For example, mRNA levels for vGAT, GABRA1, GAD67, and parvalbumin all increased with age.
CONCLUSIONS: Together with published reports, these findings support the interpretation that the altered expression of GABA-related transcripts in schizophrenia reflects a blunting of normal postnatal development changes, but they cannot exclude a decline during the early stages of clinical illness.
© The Author 2013. Published by Oxford University Press on behalf of the Maryland Psychiatric Research Center. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  GABA; neurodevelopment; parvalbumin; prefrontal cortex; schizophrenia

Mesh:

Substances:

Year:  2013        PMID: 24361861      PMCID: PMC4266281          DOI: 10.1093/schbul/sbt178

Source DB:  PubMed          Journal:  Schizophr Bull        ISSN: 0586-7614            Impact factor:   9.306


  63 in total

1.  Maturation of cognitive processes from late childhood to adulthood.

Authors:  Beatriz Luna; Krista E Garver; Trinity A Urban; Nicole A Lazar; John A Sweeney
Journal:  Child Dev       Date:  2004 Sep-Oct

2.  Synaptogenesis in the prefrontal cortex of rhesus monkeys.

Authors:  J P Bourgeois; P S Goldman-Rakic; P Rakic
Journal:  Cereb Cortex       Date:  1994 Jan-Feb       Impact factor: 5.357

3.  Alterations in GABA-related transcriptome in the dorsolateral prefrontal cortex of subjects with schizophrenia.

Authors:  T Hashimoto; D Arion; T Unger; J G Maldonado-Avilés; H M Morris; D W Volk; K Mirnics; D A Lewis
Journal:  Mol Psychiatry       Date:  2007-05-01       Impact factor: 15.992

4.  Conserved regional patterns of GABA-related transcript expression in the neocortex of subjects with schizophrenia.

Authors:  Takanori Hashimoto; H Holly Bazmi; Karoly Mirnics; Qiang Wu; Allan R Sampson; David A Lewis
Journal:  Am J Psychiatry       Date:  2008-02-15       Impact factor: 18.112

Review 5.  Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review.

Authors:  Theresa H M Moore; Stanley Zammit; Anne Lingford-Hughes; Thomas R E Barnes; Peter B Jones; Margaret Burke; Glyn Lewis
Journal:  Lancet       Date:  2007-07-28       Impact factor: 79.321

Review 6.  Calcium binding protein markers of GABA deficits in schizophrenia--postmortem studies and animal models.

Authors:  Gavin P Reynolds; Zuhal Abdul-Monim; Joanna C Neill; Zhi-Jun Zhang
Journal:  Neurotox Res       Date:  2004       Impact factor: 3.911

7.  GABAA receptor subunit gene expression in human prefrontal cortex: comparison of schizophrenics and controls.

Authors:  S Akbarian; M M Huntsman; J J Kim; A Tafazzoli; S G Potkin; W E Bunney; E G Jones
Journal:  Cereb Cortex       Date:  1995 Nov-Dec       Impact factor: 5.357

8.  Molecular determinants of dysregulated GABAergic gene expression in the prefrontal cortex of subjects with schizophrenia.

Authors:  Nikolaos Mellios; Hsien-Sung Huang; Stephen P Baker; Marzena Galdzicka; Edward Ginns; Schahram Akbarian
Journal:  Biol Psychiatry       Date:  2009-01-01       Impact factor: 13.382

9.  Prefrontal GABA(A) receptor alpha-subunit expression in normal postnatal human development and schizophrenia.

Authors:  Carlotta E Duncan; Maree J Webster; Debora A Rothmond; Sabine Bahn; Michael Elashoff; Cynthia Shannon Weickert
Journal:  J Psychiatr Res       Date:  2010-01-25       Impact factor: 4.791

10.  Rethinking schizophrenia in the context of normal neurodevelopment.

Authors:  Vibeke S Catts; Samantha J Fung; Leonora E Long; Dipesh Joshi; Ans Vercammen; Katherine M Allen; Stu G Fillman; Debora A Rothmond; Duncan Sinclair; Yash Tiwari; Shan-Yuan Tsai; Thomas W Weickert; Cynthia Shannon Weickert
Journal:  Front Cell Neurosci       Date:  2013-05-15       Impact factor: 5.505

View more
  65 in total

1.  Elevated viral restriction factor levels in cortical blood vessels in schizophrenia.

Authors:  Benjamin I Siegel; Elizabeth J Sengupta; Jessica R Edelson; David A Lewis; David W Volk
Journal:  Biol Psychiatry       Date:  2013-09-30       Impact factor: 13.382

Review 2.  Using human brain imaging studies as a guide toward animal models of schizophrenia.

Authors:  S S Bolkan; F Carvalho Poyraz; C Kellendonk
Journal:  Neuroscience       Date:  2015-05-30       Impact factor: 3.590

Review 3.  Searching for Cross-Diagnostic Convergence: Neural Mechanisms Governing Excitation and Inhibition Balance in Schizophrenia and Autism Spectrum Disorders.

Authors:  Jennifer H Foss-Feig; Brendan D Adkinson; Jie Lisa Ji; Genevieve Yang; Vinod H Srihari; James C McPartland; John H Krystal; John D Murray; Alan Anticevic
Journal:  Biol Psychiatry       Date:  2017-03-14       Impact factor: 13.382

4.  Altered Markers of Cortical γ-Aminobutyric Acid Neuronal Activity in Schizophrenia: Role of the NARP Gene.

Authors:  Sohei Kimoto; Mark M Zaki; H Holly Bazmi; David A Lewis
Journal:  JAMA Psychiatry       Date:  2015-08       Impact factor: 21.596

5.  Developmental Expression Patterns of GABAA Receptor Subunits in Layer 3 and 5 Pyramidal Cells of Monkey Prefrontal Cortex.

Authors:  Dibyadeep Datta; Dominique Arion; David A Lewis
Journal:  Cereb Cortex       Date:  2014-03-07       Impact factor: 5.357

Review 6.  Impaired Tuning of Neural Ensembles and the Pathophysiology of Schizophrenia: A Translational and Computational Neuroscience Perspective.

Authors:  John H Krystal; Alan Anticevic; Genevieve J Yang; George Dragoi; Naomi R Driesen; Xiao-Jing Wang; John D Murray
Journal:  Biol Psychiatry       Date:  2017-01-13       Impact factor: 13.382

7.  The Neurobiological Basis for Social Affiliation in Autism Spectrum Disorder and Schizophrenia.

Authors:  Amanda Crider; Anilkumar Pillai
Journal:  Curr Behav Neurosci Rep       Date:  2016-04-16

8.  Lower glutamic acid decarboxylase 65-kDa isoform messenger RNA and protein levels in the prefrontal cortex in schizoaffective disorder but not schizophrenia.

Authors:  Jill R Glausier; Sohei Kimoto; Kenneth N Fish; David A Lewis
Journal:  Biol Psychiatry       Date:  2014-05-29       Impact factor: 13.382

9.  Altered expression of developmental regulators of parvalbumin and somatostatin neurons in the prefrontal cortex in schizophrenia.

Authors:  David W Volk; Jessica R Edelson; David A Lewis
Journal:  Schizophr Res       Date:  2016-03-10       Impact factor: 4.939

Review 10.  Layer 3 Excitatory and Inhibitory Circuitry in the Prefrontal Cortex: Developmental Trajectories and Alterations in Schizophrenia.

Authors:  Gil D Hoftman; Dibyadeep Datta; David A Lewis
Journal:  Biol Psychiatry       Date:  2016-06-04       Impact factor: 13.382

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.